GET DAILY SIGNALSTriSalus Life Sciences (TLSI): Path to the $10 Target and a +210% Move
Key Takeaways
- The central $10 stock price target is the arithmetic mean of five verified analyst price targets collected (rounded from $10.40), not a single analyst's view.
- The latest verified price is approximately $3.22, meaning reaching $10 would require a roughly 210% gain — a very large move.
- Individual analyst targets span a wide range, from a low of $7 (Canaccord Genuity) to a high of $14 (Maxim Group), and all five ratings are Buy.
- The strongest supports are commercial-stage FDA-cleared technology, expected revenue growth, and a uniformly bullish analyst stance.
- The biggest risks are an unprofitable business model, shareholder dilution from equity financings, and a volatile micro-cap share price.
- For more detail on this ticker, visit the Major News and Today's Price Move pages, or check the Forecast and Earnings pages.
- Readers can also explore Trending AI Robots for AI-driven market analysis.
Analyst Price Targets and Consensus View
TLSI is the ticker for TriSalus Life Sciences, Inc., an oncology-focused medical technology company based in Westminster, Colorado that develops pressure-enabled drug delivery systems for liver and pancreatic tumors. Five current analyst price targets were reviewed: H.C. Wainwright at $12 (October 2026), Maxim Group at $14 (August 2026), JonesTrading at $11 (August 2026), Lake Street at $8 (September 2026), and Canaccord Genuity at $7 (September 2026). The average of these five figures is $10.40, which rounds to a central target of $10.
The range is unusually wide — $7 to $14 — reflecting genuine disagreement about how quickly the company's commercial ramp will translate into value. Every covering analyst rates the stock a Buy, and independent data providers describe the consensus as "Strong Buy." Analysts have been moving targets in both directions, which is notable: H.C. Wainwright raised its target from $11 to $12, while Lake Street lowered its target from $10 to $8 and Canaccord Genuity reiterated $7. The bullish core argument across the notes is that TriSalus's FDA-cleared TriNav infusion device and its investigational immunotherapy approach address a large, underserved market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The latest verified price is roughly $3.22, near the lower end of a 52-week range of approximately $2.20 to $7.95. Reaching the $10 central target would require a move of about 210% — a very large advance for any stock and especially demanding for a company still scaling toward profitability. With a market capitalization of roughly $200 million and a negative P/E (price-to-earnings) ratio, TriSalus remains in a growth investment phase.
A credible path toward the target would depend on sustained commercial execution: expanding utilization of its drug-delivery systems, growing revenue each quarter, progressing its clinical pipeline, and eventually moving toward operating breakeven. Because the stock trades at a low price, its day-to-day percentage swings can be sharp, which makes both rapid advances and drawdowns more likely.
What Could Support a Move Toward the Target
- Commercial-stage, FDA-cleared technology: The company sells an approved delivery device, giving it real revenue rather than purely pre-clinical promise.
- Large addressable market: Liver and pancreatic tumors are areas of significant unmet need, supporting the analyst growth thesis.
- Uniformly positive analyst stance: All five covering analysts rate the stock Buy, and one firm raised its target as recently as October 2026.
- Expanding revenue base: Quarterly revenue growth, when reported, is the key fundamental driver analysts cite for a higher valuation.
What Could Prevent the Target From Being Reached
- Ongoing losses: The company is not yet profitable, so valuation depends heavily on future execution rather than current earnings.
- Dilution risk: TriSalus has used equity financing arrangements, including a standby equity purchase agreement, which can pressure the share price by issuing new shares.
- Micro-cap volatility: With a roughly $200 million market cap, the stock is sensitive to small changes in volume, sentiment, and liquidity.
- Clinical and commercial execution risk: Adoption of its systems and pipeline progress must be delivered steadily; any setback could widen the gap to analyst targets.
- Wide analyst range: The gap between the $7 low and $14 high shows analysts themselves are uncertain about the pace and magnitude of upside.
Technical Levels and Market Structure
The stock trades near the bottom of its 52-week range after a notable decline from its roughly $7.95 peak. The $7 to $8 zone, where several analysts place their lower targets, also represents a prior trading area and could act as a resistance level on any recovery. Above that, the round-number $10 level is the central target and a psychological barrier. On the downside, the 52-week low near $2.20 is the key support level to watch, as a breach below it would indicate further deterioration in market structure. From what I see, monitoring these levels closely helps frame realistic expectations.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though the exact horizon varies by firm. Investors should monitor quarterly earnings and revenue, commentary on device utilization and pipeline progress, any new analyst revisions or target changes, and announcements regarding financing or capital raises. Broader healthcare-sector sentiment and small-cap market conditions also matter, since micro-cap stocks are disproportionately affected by shifts in risk appetite. I’m watching this closely as quarterly updates come in.
Final Assessment
The question of whether TriSalus Life Sciences (TLSI) can reach $10 depends on whether the company can convert its commercial-stage, FDA-cleared technology into sustained revenue growth and, eventually, profitability. The $10 target is the average of five Buy-rated analyst targets ranging from $7 to $14, and it implies a very large move of roughly 210% from the latest price near $3.22. Bullish analysts point to a large unmet medical need and a uniform Buy consensus; the principal obstacles are ongoing losses, dilution risk, and the volatility inherent in a micro-cap stock. The wide target range signals meaningful uncertainty, and no outcome is guaranteed. Investors should watch quarterly results, analyst revisions, and financing news closely.
Exploring AI Daily Buy/Sell Signals for Deeper Insights
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a useful resource for tracking momentum shifts across stocks like this one. The tool applies artificial intelligence to scan thousands of securities in real time, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For a name like TLSI, it provides an efficient way to stay aligned with evolving trends without relying solely on manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TLSI's Indicator enters downward trend
The Aroon Indicator for TLSI entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator formed such a pattern. In 139 of the 165 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLSI as a result. In 55 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for TLSI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 33 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
The 50-day moving average for TLSI moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLSI's RSI Indicator exited the oversold zone, 21 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +8.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSI advanced for three days, in 136 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
TLSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TLSI's P/B Ratio (30.552) is slightly higher than the industry average of (4.142). P/E Ratio (-2.444) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.459) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. TLSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement